Premium
P3‐156: Validating Plasma Metabolomics Signatures of Alzheimer’s Disease
Author(s) -
Niedzwiecki Megan M.,
Walker Douglas,
Watts Kelly D.,
Hu William T.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1816
Subject(s) - metabolomics , metabolite , metabolome , cohort , cerebrospinal fluid , computational biology , disease , alzheimer's disease neuroimaging initiative , bioinformatics , medicine , biology , oncology , pharmacology , alzheimer's disease
CNS. We analyzed the thyroid hormones as potential biomarkers for Alzheimer’s disease. Methods: Were invited to participate in this experiment, 120 elderly, and willing: without AD Group: 60 cognitively healthy individuals with no diagnosis of AD, aged less than 60 years old, coming from the Laboratory of Vestibular Rehabilitation Master’s Program in Vestibular Rehabilitation and Social University Anhanguera in Sao Paulo Brazil. Group with AD: 60 patients diagnosed with probable AD, coming from the Geriatrics Center in Cuiaba Brazil The following blood tests were performed: Glucose. Total cholesterol. Triglycerides. Folic Acid, Vitamin B12. triiodothyronine (T3), thyroxine (T4) and thyroid stimulating hormone (TSH). Results:Our results demonstrate that in patients with AD, T4 levels are about 10 times higher than normal, suggesting that along the development occurs a reduction in expression of isoform of the enzyme D2 or oxidative neurodegeneration cholinergic accompanying this disease, contributes to a reduction of the enzymatic activity D2. The hemoglobin and platelet concentrations are statistically lower in patients with AD. These data are consistent with the literature that lower levels of hemoglobin are associated with cognitive impairment in AD (FAUX et al, 2014; KIM et al, 2013). Other factors related to the functioning of the hematologic system are also directly altered in patients with AD, such as homocysteine, vitamin B12 and folate. These data reinforce the homocysteine association present in plasma with cognitive impairment, although not unique to DA (Faux et al., 2011), but these changes may also be associated with cases of depression (Coppen, Bolander-Gouaille, 2005). Conclusions: The reduction of neuronal mediated by hemoglobin oxygenation, can induce cholinergic and glutamatergic neurons to an anaerobic metabolism, free radical generating reactive forms of oxygen. Our results also demonstrate that patients with AD have significant changes in thyroid activity, increasing T4 levels and reducing levels of T3. P3-156 VALIDATING PLASMA METABOLOMICS SIGNATURES OFALZHEIMER’S DISEASE